2022
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
Powell L, L’Italien G, Popoff E, Johnston K, O’Sullivan F, Harris L, Croop R, Coric V, Lipton R. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305). Advances In Therapy 2022, 40: 585-600. PMID: 36417057, PMCID: PMC9898331, DOI: 10.1007/s12325-022-02369-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansMigraine DisordersPiperidinesPyridinesQuality of LifeSurveys and QuestionnairesConceptsOpen-label extensionEQ-5D utilitiesWeek 12EQ-5DLong-term health-related qualityDouble-blind treatment phaseDouble-blind treatmentPrevention of migraineHealth-related qualityLife Questionnaire version 2.1Migraine-Specific QualityInfluence of treatmentHRQoL improvementResultsBaseline dataIntroductionThe objectiveAdult patientsPoint patientsActive treatmentTrial armsHRQOL measuresPreventive effectPreventive treatmentPlaceboLabel extensionTreatment phaseReal-World experience of interictal burden and treatment in migraine: a qualitative interview study
Lo S, Gallop K, Smith T, Powell L, Johnston K, Hubig L, Williams E, Coric V, Harris L, L’Italien G, Lloyd A. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study. The Journal Of Headache And Pain 2022, 23: 65. PMID: 35676636, PMCID: PMC9174626, DOI: 10.1186/s10194-022-01429-5.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCalcitonin Gene-Related PeptideHumansMigraine DisordersQualitative ResearchQuality of LifeSurveys and QuestionnairesConceptsMigraine attacksInterictal burdenMigraine symptomsPreventive treatmentHealth-related qualityMonoclonal antibody treatmentSubgroup of patientsEffective treatment optionSelf-reported diagnosisBreakthrough attacksCGRP mAbsHRQL impactAntibody treatmentMigraine painMigraine treatmentTreatment optionsTreatment administrationQualitative interview studyMigraine impactLifestyle changesPatient's perspectiveTreatment experienceSide effectsPatient experienceConclusionThis study
2021
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
Johnston K, L’Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton R. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Advances In Therapy 2021, 38: 5209-5220. PMID: 34455556, PMCID: PMC8478726, DOI: 10.1007/s12325-021-01897-2.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsHumansMigraine DisordersPiperidinesPyridinesQuality of LifeSurveys and QuestionnairesConceptsMonthly migraine daysPRN groupMigraine-Specific QualityEQ-5DPRN armLong-term safety studiesHealth state utilitiesMigraine daysEpisodic migraineMethodsStudy participantsTreatment regimensWeek 12Study visitNeurological conditionsSafety studiesBaselineDay scheduleState utilitiesPatientsUtility valuesPRNOutcomesQODGroupDaysMatching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L’Italien G, Moren J. Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine. Headache The Journal Of Head And Face Pain 2021, 61: 906-915. PMID: 34021585, PMCID: PMC8361942, DOI: 10.1111/head.14128.Peer-Reviewed Original ResearchConceptsMonthly migraine daysMatching-adjusted indirect comparisonHealth-related qualityEVOLVE trialSTRIVE trialBaseline characteristicsMigraine daysIndirect comparisonSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistLong-term preventive effectsAnti-CGRP monoclonal antibodiesMean differencePlacebo-controlled trialPeptide receptor antagonistSingle-arm trialTreatment of migraineVersion 2 scoreMigraine-Specific QualityAssessment test scoreAcute treatmentRandomized trialsWeek 12HRQoL dataReceptor antagonist